Literature DB >> 14325881

COMPARATIVE IN VITRO ACTIVITIES OF LYSOSTAPHIN AND OTHER ANTISTAPHYLOCOCCAL ANTIBIOTICS ON CLINICAL ISOLATES OF STAPHYLOCOCCUS AUREUS.

E F HARRISON, C B CROPP.   

Abstract

The in vitro activity of lysostaphin against clinical isolates of Staphylococcus aureus was determined by conventional tube-dilution methods. For comparison, minimal inhibitory concentration (MIC) values were also determined for penicillin G, ampicillin, methicillin, ristocetin, vancomycin, and erythromycin. Phage type and penicillinase and coagulase production were determined for each isolate. The MIC values for lysostaphin ranged from <0.047 to 12.5 mug/ml; 96% of the penicillinase-positive strains were inhibited by 1.56 mug/ml of lysostaphin, whereas 3.12 mug/ml of vancomycin and methicillin were required to attain the same degree of inhibition.

Entities:  

Keywords:  AMPICILLIN; ANTIBIOTICS; BACTERIOLYSIS; BACTERIOPHAGE TYPING; COAGULASE; ERYTHROMYCIN; EXPERIMENTAL LAB STUDY; METHICILLIN; PENICILLIN G; PENICILLINASE; RISTOCETIN; STAPHYLOCOCCAL PHAGES; STAPHYLOCOCCUS; VANCOMYCIN

Mesh:

Substances:

Year:  1965        PMID: 14325881      PMCID: PMC1058223          DOI: 10.1128/am.13.2.212-215.1965

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  11 in total

1.  LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS.

Authors:  C A SCHINDLER; V T SCHUHARDT
Journal:  Proc Natl Acad Sci U S A       Date:  1964-03       Impact factor: 11.205

2.  THE NEW PENICILLINS.

Authors:  J O KLEIN; M FINLAND
Journal:  N Engl J Med       Date:  1963-11-14       Impact factor: 91.245

3.  IN VITRO ACTIVITY OF PENICILLINS AGAINST STAPHYLOCOCCUS ALBUS.

Authors:  J O KJELLANDER; J O KLEIN; M FINLAND
Journal:  Proc Soc Exp Biol Med       Date:  1963 Aug-Sep

4.  THE IN VITRO EFFECT OF LYSOSTAPHIN ON CLINICAL ISOLATES OF STAPHYLOCOCCUS AUREUS.

Authors:  C B CROPP; E F HARRISON
Journal:  Can J Microbiol       Date:  1964-12       Impact factor: 2.419

5.  Origin of erythromycin-resistant strains of Micrococcus pyogenes in infections; bacteriophage types and in vitro resistance of cultures to antibiotics.

Authors:  R I WISE; A E VOIGT; M V COLLIN; C L CRANNY
Journal:  AMA Arch Intern Med       Date:  1955-03

6.  Chemotherapeutic studies on a new antibiotic-BRL.1241.

Authors:  D M BROWN; P ACRED
Journal:  Lancet       Date:  1960-09-10       Impact factor: 79.321

7.  The techniques and interpretation of phage typing of staphylococci.

Authors:  J E BLAIR; M CARR
Journal:  J Lab Clin Med       Date:  1960-04

8.  Modified Gots test for penicillinase production.

Authors:  T H HAIGHT; M FINLAND
Journal:  Am J Clin Pathol       Date:  1952-08       Impact factor: 2.493

9.  Antistaphylococcal activity of sodium methicillin: 2,6-dimethoxyphenyl penicillin; penicillin X-1497.

Authors:  A WHITE; D T VARGA
Journal:  Arch Intern Med       Date:  1961-11
View more
  6 in total

1.  [Studies with lysotaphin. II. Lysostaphin sensitivity of 230 strains of Staph. aureus of animal origin].

Authors:  G Pulverer
Journal:  Z Med Mikrobiol Immunol       Date:  1968

2.  Lysostaphin in experimental renal infections.

Authors:  E F Harrison; W A Zygmunt
Journal:  J Bacteriol       Date:  1967-02       Impact factor: 3.490

3.  MICROBIOLOGICAL ACTIVITIES OF LYSOSTAPHIN AND PENICILLINS AGAINST BACTERIOPHAGE 80/81 STRAINS OF STAPHYLOCOCCUS AUREUS.

Authors:  W A ZYGMUNT; E F HARRISON; H P BROWDER
Journal:  Appl Microbiol       Date:  1965-05

4.  Rapid identification of Staphylococcus aureus by using lysostaphin sensitivity.

Authors:  P J Severance; C A Kauffman; J N Sheagren
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

5.  Influence of blood and serum on the antistaphylococcal activity of lysostaphin.

Authors:  W A Sygmunt; H P Browder; P A Tavormina
Journal:  J Bacteriol       Date:  1966-02       Impact factor: 3.490

Review 6.  Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications.

Authors:  Maria do Carmo de Freire Bastos; Bruna Gonçalves Coutinho; Marcus Lívio Varella Coelho
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.